|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 47/68 | |
| A61K 45/06 | |||
| A61K 31/46 | |||
| A61K 31/4375 | |||
| A61P 35/00 |
| (11) | Patento numeris | 2629801 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 11835158.4 |
| Europos patento paraiškos padavimo data | 2011-10-20 | |
| (97) | Europos patento paraiškos paskelbimo data | 2013-08-28 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2019-05-15 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/US2011/057130 |
| Data | 2011-10-20 |
| (87) | Numeris | WO 2012/054748 |
| Data | 2012-04-26 |
| (30) | Numeris | Data | Šalis |
| 201161445785 P | 2011-02-23 | US | |
| 405767 P | 2010-10-22 | US |
| (72) |
LEWIS, Timothy S., US
LAW, Che-Leung, US
MCEARCHERN, Julie A., US
|
| (73) |
Seattle Genetics, Inc.,
21823 30th Drive, S.E., Bothell, WA 98021,
US
|
| (54) | SYNERGISTIC EFFECTS BETWEEN AURISTATIN-BASED ANTIBODY DRUG CONJUGATES AND INHIBITORS OF THE PI3K-AKT MTOR PATHWAY |
| SYNERGISTIC EFFECTS BETWEEN AURISTATIN-BASED ANTIBODY DRUG CONJUGATES AND INHIBITORS OF THE PI3K-AKT MTOR PATHWAY |